U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07862764) titled 'A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections' on Oct. 02.
Brief Summary: Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) represents approximately 50% of all newly diagnosed patients with non-Hodgkin lymphoma. This study will assess adverse events and change in disease activity in adult Korean participants with DLBCL under routine clinical practice.
Epcoritamab is an approved drug for the treatment of DLBCL and FL. Approximately 175 adult participant...